Insider buying last 90 days
No open-market insider purchases were filed for VIR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every VIR insider filing, plotted on the chart in Gekko.Open VIR in Gekko
NASDAQ: VIR
Vir Biotechnology (VIR) Stock Analysis & Forecast
Oct 12 close
$11.30−0.40 (−3.4%)
Gekko Brief
AI summaryOct 12 closeVIR receives FDA Fast Track designation for VIR-5500, its PSMA-targeted T-cell engager co-developed with Astellas Pharma, for late-line metastatic castration-resistant prostate cancer. The company also appointed Dr. David Liu as Executive Vice President and Chief Medical Officer, taking charge of clinical development, medical affairs and regulatory functions. Alongside this, Argus raised its target price for VIR to $12.00, while shares also touched a 52-week high of $11.96 during the week, even as one report noted a 6.5% drop to $10.78 amid mixed analyst opinion.
VIR closed at $11.30, down 3.4% on the day, with the price sitting above both the 50-day average of $10.47 and the 200-day average of $9.19. The GekkoIndex reads 54.2, placing the stock in the Neutral zone. Price remains 21.7% below the Gekko Fair Value of $14.44.
Looking ahead, VIR next reports earnings on 4 November 2026, after the close, which falls within the next 20 trading days and inside a typical holding window for swing positions. At the last earnings release on 5 August 2026, actual EPS of $0.47 missed the $0.83 estimate, with shares reacting -4.4%; the average absolute post-earnings move has run 11.4%. No insider, Congress or unusual options activity appears in the recent windows. Seasonally, the next 20 trading days have averaged a 6.3% return over 5 years, though gains occurred in only 2 of those years, a pattern worth noting given the upcoming report.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Vir Biotechnology price vs fair value
Close $11.30200-day averageGekko Fair Value $14.44
Vir Biotechnology quick facts
- Market cap
- $1.91B
- P/E ratio
- —
- Forward P/E
- 4.3
- EPS, TTM
- −$1.70
- Revenue, TTM
- $303.2M
- Profit margin
- -83%
- Dividend yield
- —
- Beta
- 1.59
- Volume
- 1.09M avg 2.31M
- 1-year return
- +87.1%
- Typical daily move
- ±6%
- Typical 20-day move
- ±11.7%
- 50-day average
- $10.47
- 200-day average
- $9.19
- Next earnings
- Nov 4 after close
- Shares outstanding
- 169.2M
Vir Biotechnology swing-trade checklist
Vir Biotechnology scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $11.30 is above the 50-day ($10.47) and 200-day ($9.19) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
54.2, Neutral
Reading 54.2 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
21.7% below
Price is 21.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+6.3% on average
From this point in the calendar, the next 20 trading days averaged +6.3% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Vir Biotechnology stock chart and price history
Vir Biotechnology closed at $11.30 on Oct 12, 2026, +87.1% over the past year, inside a 52-week range of $4.82 to $12.00.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +6.4%
- 3 months
- +19.1%
- 6 months
- +21.4%
- 1 year
- +87.1%
The full VIR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open VIR in Gekko
Follow Vir Biotechnology through every session
Put VIR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track VIR in GekkoFree for 7 days. No credit card required.
About Vir Biotechnology
Vir Biotechnology works in immunology, developing medicines aimed at treating and preventing serious infectious diseases, and it already has products on the market. Its development work includes sotrovimab, sold as Xevudy, a monoclonal antibody used against SARS-CoV-2, along with candidates aimed at hepatitis B, influenza A and HIV prevention.
Much of the company's progress depends on outside partnerships rather than working alone. It receives grant funding from groups such as the Bill & Melinda Gates Foundation and the National Institutes of Health, and has licensing or option deals with firms including Brii Biosciences and Alnylam Pharmaceuticals. Additional licensing ties connect it to The Rockefeller University and MedImmune, while collaborations with WuXi Biologics, Glaxo Wellcome UK and GlaxoSmithKline Biologicals support its research. Manufacturing for its SARS-CoV-2 antibody work is handled under contract with Samsung Biologics, and Gilead Sciences partners with it on chronic hepatitis B development.
Vir Biotechnology was founded in 2016 and is based in San Francisco, California. Its shares are listed on the NASDAQ under the ticker VIR.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- vir.bio
Vir Biotechnology GekkoIndex: the smart money zone
Vir Biotechnology’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 54.2, in the Neutral zone, up 4.5 points over five sessions.
54.2Neutral
Up 4.5 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 46 | +0.6% | +11.2% | ||
| Accumulation | 245 | +1.1% | +4.7% | ||
| Neutral (current zone) | 365 | +0.6% | −0.4% | ||
| Distribution | 23 | −4.9% | −11.4% | ||
| Selling | 3 | Too few readings yet | |||
Average VIR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the VIR price, zone by zone.Track VIR in Gekko
Is Vir Biotechnology stock overvalued? Gekko Fair Value
Vir Biotechnology trades 21.7% below Gekko Fair Value of $14.44, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Vir Biotechnology shares are worth, recalculated every trading day.
$14.44
Gekko Fair Value, Oct 10, 2026
21.7% Undervalued
At the end of Aug 2026 the price was 35.7% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open VIR in Gekko
Vir Biotechnology insider and Congress trading
No open-market insider purchases were filed for Vir Biotechnology, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in VIR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for VIR, plotted on the chart in Gekko.Open VIR in Gekko
Buybacks
Vir Biotechnology has been buying back its own shares.
- Bought back, year ended Dec 31, 2019
- $3K
- As a share of market cap
- 0.00%
From company filings.
Vir Biotechnology earnings: next date and track record
Vir Biotechnology reports on Nov 4, 2026, after the close (23 days away), and beat the EPS estimate in 2 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 23 days away
- EPS estimate
- −$0.74
- Revenue estimate
- $865K
2 of 8reports beat the EPS estimate
±11.4%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- Vir Biotechnology completed enrollment in ECLIPSE 2 during Q2 2026, with top-line data from ECLIPSE 1 expected Q4 2026 and ECLIPSE 2/3 readouts in Q1 2027. The company presented 96-week SOLSTICE trial data at EASL Congress, generating strong KOL interest. VIR-5500, their PSMA-targeted T-cell engager partnered with Astellas, is enrolling expansion cohorts in prostate cancer. Bulevirtide's approval is seen as a commercial tailwind for their hepatitis delta program.
- Guidance
- Top-line data from ECLIPSE 1 expected Q4 2026, followed by ECLIPSE 2 and ECLIPSE 3 readouts in Q1 2027. Management is accelerating VIR-5500 clinical development in prostate cancer across monotherapy and combination cohorts to inform future registrational trials.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $0.47 est $0.83 | $238.9M est $135.9M | −4.4% |
| May 6, 2026 | −$0.85 est $0.48 | −$29K est $55.49M | −7.4% |
| Feb 23, 2026 | −$0.31 est −$0.42 | $64.07M est $19.91M | +25.5% |
| Nov 5, 2025 | −$1.17 est −$0.70 | $240K est $19.91M | −2.5% |
| Aug 6, 2025 | −$0.80 est −$0.72 | $1.21M est $2.72M | −14.9% |
| May 7, 2025 | −$0.88 est −$0.83 | $1.79M est $8.59M | −3.9% |
| Feb 26, 2025 | −$0.76 est −$0.85 | $12.37M est $8.14M | −10.9% |
| Oct 31, 2024 | −$1.56 est −$0.96 | $2.38M est $9.37M | +21.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Vir Biotechnology stock forecast and analyst price targets
Analysts’ average 12-month price target for Vir Biotechnology is $21.00, +85.8% from the last close, from 8 firms rating the stock in the last 90 days.
$21.00consensus 12-month target, +85.8% from the last close
Now $11.30Avg $21.00
Low $15High $30
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 8 | Barclays | $30 | +165.5% |
| Oct 7 | H.C. Wainwright | $22 | +94.7% |
| Sep 29 | Leerink Partners | $17 | +50.4% |
| Sep 28 | Needham | $18 | +59.3% |
| Sep 21 | H.C. Wainwright | $20 | +77.0% |
−0.4%average 20-day move after past Neutral readings
+6.3%average move over the next 20 trading days in the last 5 years
±6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Vir Biotechnology seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Vir Biotechnology averaged +6.3% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.4% | 2 of 5 |
| Next 10 trading days | +1.4% | 4 of 5 |
| Next 15 trading days | −1.7% | 3 of 5 |
| Next 20 trading days | +6.3% | 2 of 5 |
| Next 30 trading days | +0.1% | 2 of 5 |
For scale, VIR’s typical 20-trading-day move in either direction is about 11.7%.
Vir Biotechnology market cap and key statistics
Vir Biotechnology’s market cap is $1.91B and revenue of $303.2M over the last twelve months.
Valuation
- Market cap
- $1.91B
- Forward P/E
- 4.3
- EPS, TTM
- −$1.70
- Gekko Fair Value
- $14.44
Trading
- Volume
- 1.09M
- Avg volume, 20 days
- 2.31M
- 52-week high
- $12.00
- 52-week low
- $4.82
- Shares outstanding
- 169.2M
Financials
- Revenue, TTM
- $303.2M
- Profit margin
- -83%
- Return on equity
- -26.1%
- Quarterly earnings growth, YoY
- +58.5%
Risk and income
- Beta
- 1.59
- Typical daily move
- ±6%
- Typical 20-day move
- ±11.7%
Vir Biotechnology stock news this week
Coverage of Vir Biotechnology this week reads positive: 10 positive, 3 neutral and 1 negative headlines.
- Vir Biotechnology, Inc. (VIR) Stock forecastsYahoo Finance UK, Oct 12
- Vir Biotechnology stock hits 52-week high at 11.96 USD By Investing.comInvesting.com Canada, Oct 9
- FDA grants fast track designation to VIR-5500 for mCRPCUrology Times, Oct 9
- Vir Biotechnology gains FDA Fast Track for VIR-5500TipRanks, Oct 9
- Vir Biotechnology (NASDAQ:VIR) Shares Down 6.5% - Here's What HappenedMarketBeat, Oct 8
- Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate CancerBusiness Wire, Oct 8
Vir Biotechnology peers
Vir Biotechnology’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Vir Biotechnology stock FAQ
What is Vir Biotechnology’s market cap?
Vir Biotechnology’s market cap is $1.91B at the Oct 12, 2026 close of $11.30, with 169.2M shares outstanding.
What is the Vir Biotechnology stock forecast?
The consensus analyst 12-month price target for Vir Biotechnology is $21.00, +85.8% from the last close. Of the 8 firms that rated the stock in the last 90 days, 8 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Vir Biotechnology stock overvalued or undervalued?
On Gekko’s estimate Vir Biotechnology is undervalued: the Oct 12, 2026 close of $11.30 is 21.7% below Gekko Fair Value of $14.44. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Vir Biotechnology report earnings next?
Vir Biotechnology is expected to report on Nov 4, 2026, after the market closes (23 days away). Analysts expect earnings of −$0.74 per share on revenue of $865K. Vir Biotechnology beat the earnings estimate in 2 of its last 8 reports, moving 11.4% on average across the report.
What is Vir Biotechnology’s 52-week high and low?
Vir Biotechnology’s 52-week high is $12.00 and its 52-week low is $4.82; it closed at $11.30 on Oct 12, 2026, +87.1% over the past year. Over the last five years the shares peaked at $58.00 on Dec 20, 2021.
Is Vir Biotechnology stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and fair value), 2 as mixed (gekkoindex and seasonality) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Vir Biotechnology the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.